Supernus Pharmaceuticals, Inc.
SUPN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001356576
No open-market purchases or sales by Supernus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 334 institutions reported holding it in 13F filings for Q2 2026, worth $2.80B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Supernus Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 273 | 1 | 294 | +22 |
| Shares | 59.9M | 208.6K | 59.5M | −172.5K (−0.3%) |
| Value | $1.87B | $6.88M | $2.15B | +$291.6M (+15.7%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (42)
Institutions that held Supernus Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (20)
Institutions that held Supernus Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Jane Street Group, LLC | 52,998 | $1.65M |
| Marshall Wace, LLP | 51,139 | $1.59M |
| Tudor Investment Corp Et Al | 27,525 | $858.2K |
| Sherbrooke Park Advisers LLC | 16,956 | $528.7K |
| Azzad Asset Management Inc | 15,641 | $487.7K |
| Ingalls & Snyder LLC | 11,500 | $359.0K |
| Dynamic Technology Lab Private Ltd | 11,288 | $352.0K |
| Boothbay Fund Management, LLC | 8,184 | $255.2K |
| Rafferty Asset Management, LLC | 7,570 | $236.0K |
| Campbell & CO Investment Adviser LLC | 6,470 | $201.7K |
| Corton Capital Inc. | 6,467 | $201.6K |
| Quantbot Technologies LP | 1,026 | $32.0K |
| Catalyst Funds Management Pty Ltd | 800 | $24.9K |
| International Assets Investment Management, LLC | 686 | $22.0K |
| Point72 (DIFC) Ltd | 455 | $14.2K |
| Capital Performance Advisors LLP | 29 | $904 |
| Ronald Blue Trust, Inc. | 24 | $642 |
| CVA Family Office, LLC | 14 | $437 |
| Mendota Financial Group, LLC | 5 | $156 |
| Claris Advisors, LLC | 1 | $31 |
Not filed for Q4 2024 yet (1)
Institutions that held Supernus Pharmaceuticals, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Scout Investments, Inc. | 208,613 | $6.88M |